tert-Butyl 4-((2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate

tert-Butyl 4-((2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate is a high‑purity, pharma‑grade advanced intermediate supplied by Cosperpharm for the manufacture of diazabicyclooctane (DBO) β‑lactamase inhibitors. This compound is a key precursor to avibactam and relebactam, two life‑saving antibiotic adjuvants that restore the activity of β‑lactam antibiotics against multidrug‑resistant Gram‑negative pathogens. Because tert-butyl 4-((2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate retains the exact (2S,5R) chirality and the reactive 7‑oxo warhead, it enables the efficient construction of the DBO pharmacophore in just a few additional steps. Moreover, tert-butyl 4-((2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate serves as an advanced intermediate that has already undergone the key cyclization step, significantly shortening the synthetic route to the final API. At Cosperpharm, each batch of tert-butyl 4-((2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate is supplied with comprehensive analytical documentation to support both process development and regulatory submissions.

Product Parameters

Why Cosperpharm?

Cosperpharm is a trusted supplier of high‑purity pharmaceutical intermediates and reference standards, serving research institutions and API manufacturers across more than 30 countries. With a GMP‑compliant production campus and advanced analytical capabilities—including HPLC, LC‑MS, GC‑MS, and high‑field NMR—we ensure that every batch of tert-Butyl 4-((2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate meets stringent quality specifications. Our quality management system is aligned with ICH Q7 guidelines, and we provide full documentation packages including Certificates of Analysis (COA), HPLC chromatograms, mass spectrometry data, and stability studies to facilitate your regulatory submissions. We maintain direct sourcing relationships with raw material suppliers to ensure consistent supply and competitive pricing, and our dedicated technical support team offers responsive assistance for any product‑related inquiries. With efficient logistics and a track record of on‑time deliveries to global partners, Cosperpharm is your reliable source for this advanced DBO intermediate.

Storage Conditions

Store at 2–8°C (refrigerated) in a tightly sealed, airtight container, protected from light and moisture. Do not freeze. For long‑term storage exceeding 12 months, storage at −20°C is recommended to maintain the stability of the Boc protecting group and to prevent hydrolysis of the carboxamide linkage. Avoid repeated freeze‑thaw cycles and exposure to elevated temperatures or high humidity. Under recommended storage conditions, the product remains stable for 24 months from the date of manufacture.

Product Applications

1.Avibactam API manufacturing – a key intermediate in the multi‑step production of avibactam (NXL‑104), used in combination with ceftazidime to treat resistant Gram‑negative infections including those caused by Klebsiella pneumoniae carbapenemase (KPC)‑producing organisms.

2.Relebactam API manufacturing – an essential precursor to relebactam (MK‑7655), approved in combination with imipenem/cilastatin for the treatment of complicated urinary tract infections (cUTI) and complicated intra‑abdominal infections (cIAI).

3.Process development and scale‑up – enables monitoring of late‑stage synthetic steps, yield optimization, and impurity tracking during process scale‑up and technology transfer.

4.Analytical method development – as a fully characterized intermediate, it serves as a reference standard for HPLC, UPLC, and LC‑MS method validation, as well as chiral purity determination.

5.Impurity profiling – employed as an impurity reference standard for quality control (QC) testing during API and finished drug product release.

6.Forced degradation studies – used to identify, characterize, and quantify degradation products and process‑related impurities under ICH‑recommended stress conditions (heat, light, humidity, oxidation).

7.Regulatory submissions – ANDA, DMF, and IND filings requiring intermediate characterization with full traceability and analytical documentation.

8.New DBO inhibitor discovery – the advanced scaffold serves as a starting point for medicinal chemistry programs developing novel β‑lactamase inhibitors with improved potency or expanded spectrum of activity.

9.Antibiotic combination research – enables the synthesis of novel β‑lactamase inhibitors for combination therapy studies targeting emerging resistant pathogens.

Contact Us

Ready to advance your β‑lactamase inhibitor program with tert-Butyl 4-((2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate? Contact Cosperpharm today for a competitive quotation, product documentation, or a technical consultation with our experienced team.